The partnership will involve up to 1,000 patients and leverage the foundation’s repository of biospecimens and data to advance the development of Coral’s Functional Response Score – a precision medicine clinical test for patients with autoimmune diseases including inflammatory bowel disease
Coral Genomics, a company developing technologies to experimentally represent the diversity of humanity’s biology announced today that it has entered a partnership with the Crohn’s & Colitis Foundation, the preeminent organisation dedicated to finding cures for inflammatory bowel disease (IBD) and improving the quality of life of those affected by the condition. Coral is focusing on developing predictive diagnostic tests and working with partners on new treatments for autoimmune diseases.
“While advances in IBD treatments have enabled improvement in clinical outcomes, development of tools that can predict which therapy will work best for each individual patient is critical. IBD Plexus was designed to accelerate getting answers to this critical need, and so we were eager to work with Coral Genomics in leveraging data and bio samples housed within IBD Plexus towards achieving a shared goal of advancing progress towards precision medicine.”Angela Dobes, Vice President of IBD Plexus at the Crohn’s & Colitis Foundation.
The partnership will allow Coral to demonstrate the applicability of its tests in the IBD Plexus cohort and is part of Coral’s larger REEF studies. To date, Coral has enrolled hundreds of patients across multiple autoimmune indications.
“Medication spending on autoimmune disease in the U.S. is over $70B/yr and has recently exceeded cancer medications, but unlike cancer there are very few precision medicine solutions. Patients and doctors often face a painful trial-and-error process to find a medication that works for them. We’re working towards integrating patient clinical history, demographics, and immune cell biology towards models of what drives patient response to autoimmune therapies. The opportunity to work with the Crohn’s and Colitis Foundation and IBD Plexus will be a huge step towards validating these models. We continue to be grateful to the patients we have had the privilege to work with across our studies.”Atray Dixit, CEO of Coral.
About Coral Genomics
Founded in 2018 and headquartered in San Francisco, Coral has developed technologies to reduce the costs of genomics workflows including DNA-seq, RNA-seq, and primary cell assays. It is using these technologies to build “the Reef”, an experimental representation of humanity’s biology with a current focus on enabling precision medicine for autoimmune diseases such as IBD, Psoriasis, and Rheumatoid Arthritis. For more information, visit https://www.coralgx.com/
About the Crohn’s & Colitis Foundation
The Crohn’s & Colitis Foundation is the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease (IBD). The Foundation’s mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life for the millions of Americans living with IBD. Our work is dramatically accelerating the research process through our database and investment initiatives; we also provide extensive educational resources for patients and their families, medical professionals, and the public. For more information, visit http://www.crohnscolitisfoundation.org, call 888-694-8872, or firstname.lastname@example.org.